- Home
- HQH vs IOVA Comparison
HQH vs IOVA Comparison
Compare HQH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQH
- IOVA
- Stock Information
- Founded
- HQH 1986
- IOVA 2007
- Country
- HQH United States
- IOVA United States
- Employees
- HQH N/A
- IOVA N/A
- Industry
- HQH Finance Companies
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HQH Finance
- IOVA Health Care
- Exchange
- HQH Nasdaq
- IOVA Nasdaq
- Market Cap
- HQH 826.8M
- IOVA 771.4M
- IPO Year
- HQH N/A
- IOVA N/A
- Fundamental
- Price
- HQH $15.30
- IOVA $1.98
- Analyst Decision
- HQH
- IOVA Buy
- Analyst Count
- HQH 0
- IOVA 10
- Target Price
- HQH N/A
- IOVA $12.22
- AVG Volume (30 Days)
- HQH 183.8K
- IOVA 11.5M
- Earning Date
- HQH 01-01-0001
- IOVA 08-07-2025
- Dividend Yield
- HQH 11.56%
- IOVA N/A
- EPS Growth
- HQH N/A
- IOVA N/A
- EPS
- HQH 1.09
- IOVA N/A
- Revenue
- HQH N/A
- IOVA $212,679,000.00
- Revenue This Year
- HQH N/A
- IOVA $86.62
- Revenue Next Year
- HQH N/A
- IOVA $69.95
- P/E Ratio
- HQH $15.24
- IOVA N/A
- Revenue Growth
- HQH N/A
- IOVA 11070.12
- 52 Week Low
- HQH $14.31
- IOVA $1.64
- 52 Week High
- HQH $17.94
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- HQH 43.45
- IOVA 43.44
- Support Level
- HQH $15.28
- IOVA $1.95
- Resistance Level
- HQH $15.82
- IOVA $2.47
- Average True Range (ATR)
- HQH 0.23
- IOVA 0.15
- MACD
- HQH -0.02
- IOVA 0.05
- Stochastic Oscillator
- HQH 16.85
- IOVA 35.53
About HQH abrdn Healthcare Investors Shares of Beneficial Interest
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.